A New Era in the Operating Room: Understanding J&J’s FDA-Authorized OTTAVA™ Robotic System

Surgical technology has reached a milestone that promises to make procedures smoother, operating rooms more efficient, and patient care more seamless. On July 22, 2026, the U.S. Food and Drug Administration (FDA) granted De Novo authorization for the OTTAVA™ Robotic Surgical System, developed by Johnson & Johnson MedTech.

As the world's first table-integrated soft-tissue robotic surgical platform, OTTAVA represents a fundamental shift in how surgical robots are designed and used in hospitals nationwide.

Redesigning the Operating Room: What Makes OTTAVA Unique?

For more than two decades, conventional robotic surgery systems have relied on massive, standalone robotic carts or ceiling-mounted booms anchored around the patient. While effective, these bulky setups take up considerable floor space, restrict team movement, and require complex recalibration if a patient needs to be repositioned during surgery.

OTTAVA takes a completely different approach by building four robotic arms directly into the operating table itself.

• 30% to 50% Smaller Footprint: By eliminating separate robotic carts, OTTAVA frees up valuable floor space, allowing surgeons and nurses to move naturally around the patient.
• Synchronized "Twin Motion": The system features coordinated software that moves the table and the robotic arms together in harmony, simplifying how doctors access different areas of the abdomen.
• Automated Procedural Setup: Pre-defined system poses allow surgical teams to set up and break down equipment much faster between operations.
• Digital Ecosystem Integration: Connected to J&J’s Polyphonic™ digital network, the platform gives surgical teams real-time data insights, educational tools, and workflow guidance.

Cleared Procedures: Where OTTAVA Will Be Used

The FDA cleared OTTAVA for ten upper-abdominal general surgery procedures, covering some of the most frequently performed operations in the United States:

• Bariatric & Weight-Loss Surgeries: Roux-en-Y gastric bypass and sleeve gastrectomies.
• Abdominal & Digestive Care: Gastrectomy, small bowel resection, appendectomy, and lysis of adhesions (removing scar tissue).
• Hernia & Reflux Repairs: Hiatal hernia repair and fundoplication (treating severe GERD).
• Organ Procedures: Cholecystectomy (gallbladder removal) and splenectomy.

Why This Matters for Patients and Healthcare Teams

When operating room technology becomes less intrusive and more intuitive, everyone benefits:

• Better Team Communication: Without bulky equipment towers blocking sightlines, surgeons, anesthesiologists, and surgical nurses can maintain direct visual and physical contact throughout the operation.
• Shorter Turnaround Times: Streamlined equipment setups help hospitals run operating rooms more efficiently, which can reduce patient waiting times for elective surgeries.
• Wider Access to Advanced Care: Because OTTAVA’s compact design fits easily into standard operating rooms without requiring expensive room overhauls, more regional and community hospitals can adopt robotic surgery.

Looking Ahead: The Choice in Robotic Surgery

For years, hospitals had limited choices when investing in soft-tissue robotic platforms. The commercial launch of OTTAVA—alongside other emerging technologies—signals a dynamic new chapter where hospital systems have more flexibility to choose tools that best fit their surgeons and patients.

Johnson & Johnson is initiating a rollout with select surgical centers in the U.S. while conducting further clinical trials to expand OTTAVA into additional areas like inguinal hernia repairs. If you are preparing for an upcoming abdominal surgery, ask your surgical team about the latest minimally invasive options available in your community.

Sources & References

1. Johnson & Johnson MedTech Press Release (July 22, 2026): "Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System."
2. EMJ Reviews / Medical Device News (July 23, 2026): "Johnson & Johnson Secures FDA Nod for OTTAVA System."
3. Fierce Biotech (July 23, 2026): "FDA Clears J&J's Surgical Robot for 'The Next Era in Surgery.'"